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Anaphylaxis is an acute systemic reaction involving
symptoms of an immediate-type allergic reaction that
can comprise the whole organism and potentially be
fatal [1–3].
Although anaphylaxis is a highly acute process in
terms of its symptoms, there is a chronic immunolog-
ical imbalance underlying this condition that leads to
immediate reactions as soon as contact with the elic-
itor occurs. This chronic condition may have severe
effects of both a psychological and an organizational
nature on the everyday life of affected individuals.
The definition of anaphylaxis is not internationally
standardized. Also, a number of different classifica-
tion systems are in use. The most commonly used
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classification in German-speaking countries is used
in this guideline.
Anaphylactic reactions are among the most severe,
potentially life-threatening, and dramatic events in al-
lergology. Acute treatment is carried out according
to international guidelines and recommendations in
textbooks. This guideline is an update of earlier ver-
sions from 1994, 2007, and 2014 [4–8] and takes in-
ternational guidelines [3, 7] into consideration (see
Addendum).
Anaphylactic reactions may spontaneously cease
at any stage of symptoms, but may also progress
in severity despite adequate treatment. This unpre-
dictability makes it difficult to evaluate the efficacy of
therapeutic procedures. Single-case observations do
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not provide evidence-based information on whether
specific treatments have been effective.
It is well known that patients, e.g., after successfully
treated anaphylaxis due to an insect sting, are not op-
timally followed-up [9–11]. These problems in basic
management underline the need for further research,
as well as the importance of the guideline presented
here.
This guideline is intended for all physicians, as well
as other individuals active in health care, involved in
the acute treatment, diagnostics, and management of
patients with anaphylaxis.
Epidemiology of anaphylaxis
In recent years, a number of studies on the world-
wide prevalence of anaphylactic reactions have been
published [12–21]. Due to the varying definitions, as
well as the fact that anaphylaxis with fatal outcome is
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Table 1 Common elicitors of severe anaphylactic reac-
tions in children and adults (data from the anaphylaxis reg-










not always diagnosed, one needs to assume a certain
number of unreported cases.
A limitation with regard to data on the epidemiol-
ogy of anaphylaxis arises due to the variable coding
of anaphylaxis according to ICD-10. There are several
ICD-10 codes that can include anaphylaxis. The new
ICD-11 will be introduced in 2022, possibly with a new
classification of anaphylaxis [22–24]. There is a par-
ticular need for classification regarding whether re-
peated cutaneous reactions in manifest type I allergy
can already be regarded as anaphylaxis, whether, by
definition, involvement of at least two organ systems
is required, or whether involvement of only the res-
piratory and/or cardiovascular system can represent
a severe reaction and thus be classified as anaphy-
laxis. There is currently no national or international
consensus on this question. Published data regard-
ing epidemiology need to be evaluated taking these
aspects into consideration [25, 26].
Retrospective studies show that up to 1–2% of pa-
tients in an emergency unit at a primary care hospi-
tal (maximal care) present due to anaphylactic reac-
tions [18]. The number of anaphylaxis-related fatal-
ities is estimated to be between one and three cases
per year per million population [19]. Recent studies
from the US, UK, and Australia show incidence rates
of anaphylaxis of between 7–50/100,000 per year and
show an increased incidence of anaphylaxis in recent
decades. In particular food-induced anaphylaxis in
children and drug-induced anaphylaxis in adults have
increased, although the mortality rate has remained
unchanged [19–21].
Data from the anaphylaxis registry of German-
speaking countries, as well as data from other coun-
tries around the world, show that foods are the most
common elicitors of anaphylaxis in childhood [26]. In-
sect venoms and drugs are the most frequent elicitors
in adults (Table 1); however, there are international
differences with regard to this ranking. In childhood,
boys are more often affected by anaphylaxis than are
girls, possibly due to the more frequent occurrence
of food allergies in boys; these differences between
sexes disappear after puberty [27].
Pathophysiology
Anaphylaxis is usually caused by an immunologi-
cal reaction—most frequently an immunoglobulin E
(IgE)-mediated allergy. IgE activates mast cells and
basophils via cross-linking of high-affinity IgE re-
ceptors, leading to increased expression of surface
markers (CD63, CD203c), as indirectly measurable
on basophils. The symptoms of anaphylactic reac-
tions are mediated by a variety of substances released
from mast cells and basophil granulocytes such as
histamine, prostaglandins, leukotrienes (LTB 4, LTC 4,
and LTD 4), tryptase, platelet-activating factor (PAF),
heparin, proteases, serotonin, and cytokines [30–34].
The relative importance of these mediators in humans
cannot easily be estimated for methodological reasons
and is a matter of discussion. There is consensus that
histamine is involved in anaphylactic reactions [30].
Thus, the intravenous application of histamine can
elicit anaphylactic symptoms in healthy individu-
als [35, 36]. Furthermore, there is discussion as to
whether, in addition to IgE in rare cases (e.g., dex-
tran 4,5), other antibody classes can also elicit similar
symptoms to, or aggravate, an IgE-mediated reaction;
the complement split products, C3a, C4a, and C5a
(anaphylatoxins), are the most important mediators
in this context and, in addition to basophils, also
neutrophils and macrophages play a role as rele-
vant effector cells that can be activated via immune
complex receptors (CD16, CD32, or CD64) [37, 38].
Furthermore, there are anaphylactic reactions in
which no immunological sensitization can be de-
tected. These reactions are referred to as “pseudo-
allergic reactions” [37] or “non-immunological ana-
phylaxis” [1]. The mechanisms of this non-aller-
gic anaphylaxis include: IgE-independent release
of vasoactive mediators, possibly via MAS-related
G protein-coupled receptor [39]; direct activation
of the complement system; interactions with the
kallikrein–kinin system; interactions with arachidonic
acid metabolism; as well as psychoneurogenic reflex
mechanisms. The state of knowledge of the patho-
physiology of these reactions is undoubtedly less well
established than for allergic anaphylaxis.
Anaphylaxis can be particularly severe in patients
with increased basal serum tryptase levels and/or
mastocytosis [40–44]; however, normal tryptase levels
have often been measured, especially in children with
food-induced anaphylaxis [45]. Previous use of beta-
adrenoceptor antagonists and angiotensin converting
enzyme (ACE) inhibitors can intensify the severity of
anaphylactic symptoms [27, 28, 44, 46].
In the case of beta-adrenoceptor antagonists,
a blockade of the cardiostimulatory and mast cell-
stabilizing effects of adrenalin play a role, while ACE
inhibitors reduce bradykinin metabolism, resulting
in increased vasodilatation. The use of cyclooxy-
genase inhibitors (non-steroidal anti-inflammatory
drugs, NSAID) can also cause increased production
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Table 2 Severity scale for the classification of anaphy-
lactic reactions (modified from [6, 47]). The classification
is made according to the most severe symptoms observed













































of leukotrienes, as well as facilitated absorption of
orally ingested allergens, thereby leading to increased
anaphylactic symptoms.
Clinical symptoms
Anaphylactic reactions manifest mainly on the skin, as
well as in the respiratory tract, gastrointestinal tract,
and cardiovascular system. The working group dis-
cussed whether the guideline should use a classifi-
cation of severity grades, since current treatment is
performed according to the symptoms of anaphylaxis.
The majority favored a severity classification. There
are various classifications of anaphylaxis severity in
the literature [7, 8, 10, 29], each classification having
advantages and disadvantages. The group decided on
a modification of the currently most frequently used
classification in Germany, which was also used in the
previous guideline [5, 6]. According to the intensity of
clinical symptoms, anaphylaxis can be classified into
severity grades I–IV (Table 2).
The symptoms of anaphylactic reactions are mostly
of acute onset and can progress rapidly. Within min-
utes, symptoms can intensify and lead to shock and
death. However, the reaction can also cease sponta-
neously at any stage and resolve. With a reaction of
grade I severity, the further development and dynam-
ics of the reaction cannot be predicted. The symp-
toms may vary and occur simultaneously or sequen-
tially. There may be primary cardiovascular reactions
without preceding cutaneous or pulmonary symp-
toms. In 5–20% of affected individuals, a protracted
or biphasic clinical course may develop following
successful treatment, with renewed symptoms after
6–24h [48–50]. In addition to acute symptoms imme-
diately after allergen contact and a biphasic course,
there are also initially delayed anaphylactic reactions,
whereby the symptoms only occur some hours after
exposure. These particular kinetics have been well
documented, for example, for the allergen galactose-
alpha-1,3-galactose in mammal meat allergy (“red
meat”) and are most likely due to a delayed release or
systemic availability of the allergens or their binding
sites [51–53]. However, also in peanut allergy, the
median time from consumption to symptom onset is
55min [54].
At the start of an anaphylactic reaction, symptoms
may be observed as “prodromal symptoms” with
mild itch or a burning sensation on the palms and
soles or in the anogenital area, metallic taste, anxiety,
headache, and disorientation. Young children are un-
able to adequately report these symptoms; they often
exhibit agitation and withdrawal behavior as initial
symptoms prior to objective signs.
Itch, erythema (flush), urticaria, and angioedema
(Quincke’s edema) develop on the skin and mucous
membranes, also on skin areas that have not come
into direct contact with the elicitor (systemic reac-
tion). The skin is the organ most often affected in
anaphylaxis.
In the upper airways, patients often report a burn-
ing, prickling, or itching sensation on the tongue or
palate as initial signs. Swelling of the uvula and tongue
can be observed in the oropharynx. Clinical signs in-
clude hoarseness or muffled speech, difficulty in swal-
lowing, with salivation or inspiratory stridor. Laryn-
geal edema can potentially rapidly lead to obstruction
of the upper airways and life-threatening hypoxia.
In the lungs, bronchoconstriction and dyspnea
may develop, especially in patients with bronchial
asthma. Clinical signs include wheezing, prolonged
expiration, and tachypnea. Bronchial obstruction is
the main symptom in life-threatening reactions, espe-
cially in children and adolescents. Here, the severity
of asthma correlates directly with the severity of ana-
phylaxis. Varying degrees of vasoconstriction may
develop in some cases, with an extreme increase in
pulmonary vascular resistance occurring, sometimes
leading to respiratory arrest and need for resuscita-
tion. Pulmonary edema may occur as a result of the
impaired permeability [55–57].
Gastrointestinal symptoms include partly cramp-
like abdominal pain, nausea, vomiting, and diarrhea.
Furthermore, one may see increased intestinal mo-
tor activity involving meteorism, urge to defecate, and
even involuntary defecation. Other abdominal symp-
toms can include urge to urinate or micturition, as
well uterine cramps. In children, mild oral symp-
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toms or perioral redness with vomiting may be the
only symptoms of food-induced anaphylaxis.
As a result of vasodilatation and impaired perme-
ability, there is a loss of fluid into the tissues, lead-
ing to hemoconcentration and intravascular hypov-
olemia, followed by arterial hypotension and tachy-
cardia. Direct cardiac symptoms such as arrhythmia
or bradycardia may occur.
Symptoms of the central nervous system include
restlessness, withdrawal behavior, headache, cerebral
spasms, impaired consciousness, or loss of conscious-
ness. A change in behavior is often observed in chil-
dren, manifesting as anxiety or sometimes also ag-
gressiveness. Older children, adolescents, and adults
may experience a “sense of impending doom.”
If an anaphylactic reaction occurs during general
anesthesia, the patient is unable to report early symp-
toms such as itch or nausea. If observed, erythema,
urticaria, or cardiovascular reactions (tachycardia or
hypotension), as well as changes in bronchoconstric-
tion affecting ventilation (increased airway resistance,
decreased expiratory flow), are particularly significant
[58].
Causal factors of lethal anaphylaxis include airway
obstruction and/or cardiovascular failure, either as
a direct effect on the heart or as a sequela of impaired
microcirculation with shock; disseminated intravas-
cular coagulation or adrenaline overdose have been
observed in rare cases [59, 60].
Allergens and elicitors
The most common elicitors of severe anaphylactic re-
actions include drugs, insect venoms, and foods. The
ranking of these elicitors is determined by various
factors, such as mode of detection, age group, and
geographic region. In German-speaking countries,
elicitors of anaphylactic reactions have been regis-
tered since 2006 in an “Anaphylaxis Registry,” where
allergy centers in Germany, Austria, and Switzerland,
as well as other European countries, report cases
of severe allergic reactions. In children, foods are
the most common elicitors of severe anaphylactic
reactions, whereas insect venoms and drugs are com-
mon elicitors in adults [25]. The anaphylaxis registry
also makes it possible to promptly identify very rare
elicitors of anaphylaxis—most recently in foods, e.g.,
spices or new exotic fruits [28].
Contact with the elicitor of anaphylaxis classically
occurs via oral or parenteral (hematogenous) expo-
sure. In rare cases, anaphylaxis can also be elicited
via airborne contact or, even more rarely, via skin
contact (contact anaphylaxis) in highly sensitized in-
dividuals [61–63]. Anaphylactic symptoms may also
occur depending on a combination of various factors,
e.g., allergen exposure together with physical exer-
cise, known as exercise-induced anaphylaxis (EIA) [64,
65], alcohol, mental or emotional stress, infection, or
simultaneous exposure to other allergens, or use of
Risk factors for anaphylactic reactions
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Fig. 1 Risk factors for anaphylactic reactions
anaphylaxis-inducing drugs. This phenomenon is re-
ferred to as augmentation or summation anaphylaxis.
A more common form is food-dependent exercise-in-
duced anaphylaxis (FDEIA), which is most frequently
elicited by wheat or subspecies such as spelt, green
spelt, or emmer [65, 66].
Risk factors of severe anaphylaxis
Certain endogenous or exogenous factors can in-
crease the risk of severe anaphylaxis. Risk factors
of this kind (Fig. 1), which are independent of the
elicitor, include advanced age, severe cardiovascu-
lar disease, (inadequately treated) bronchial asthma,
use of certain drugs that promote mast cell activa-
tion or leukotriene secretion (such as NSAID), and
mastocytosis [28, 41, 67].
Evidence for an increased risk of severe anaphy-
laxis under medication with beta-adrenoceptor antag-
onists (beta-blockers) is based on a number of case
reports and case series [68–70], as well as two case
control studies on anaphylaxis frequency and severity
after administration of radiographic contrast media
[71, 72]. Recent data from the European anaphylaxis
registry confirm that the use of beta-adrenoceptor an-
tagonists is associated with an increased risk for severe
anaphylaxis (odds ratio [OR] 1.86) [28].
Considering elicitor-dependent subgroups of ana-
phylaxis, there are reports of food-induced anaphy-
laxis showing that allergic bronchial asthma is a ma-
jor risk factor [73]. Finally, the elicitor itself may be
a risk factor—it is known that primary sensitization
to peanut or fish, both highly potent allergens, repre-
sents a risk factor per se for severe reactions [74].
Diagnosis and important differential diagnoses
Since the clinical symptoms of anaphylaxis are not
always characteristic, diagnosis may be challenging.
Therefore, it is important to differentiate other acute
reactions from symptoms of anaphylaxis, such as
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Somatoform disorders (e.g., psychogenic
dyspnea, vocal cord dysfunction)
Epilepsy
Neuropsychiatric diseases
Coma, e.g., metabolic, traumatic
Acute severe asthma (without involvement
of other organs)
Acute stenosing laryngotracheitis (croup
episode)
Airway diseases
Tracheal/bronchial obstruction (e.g., foreign
body)
Skin diseases Urticarial diseases and hereditary/acquired
angioneurotic angioedema
Note: In physical urticaria, intensive contact with the elicitor may also give
rise to anaphylaxis
Ethanol






other manifestations of isolated urticaria, bronchial
obstruction, vomiting, nausea, diarrhea, agitation,
loss of consciousness, cardiac arrhythmia, and/or
cardiac arrest. Relevant differential diagnoses are
listed in Table 3. After appropriate acute treatment,
it is helpful to determine mediators in blood, in par-
ticular serum tryptase—ideally 1–3h after the onset
of anaphylaxis and, if possible, as compared to basal
serum tryptase. Tryptase can also be determined
retrospectively—even post mortem—but is not nec-
essarily elevated [41, 45, 67].
The following symptoms are considered to be char-
acteristic criteria for anaphylaxis [8]:
1. Sudden onset of skin symptoms (e.g., acute ur-
ticaria, angioedema, flush, mucosal edema) to-
gether with sudden respiratory symptoms (e.g.,
dyspnea, wheezing, cough, stridor) or a sudden
decrease in blood pressure (manifesting as, e.g.,
collapse, tachycardia, incontinence)
2. Sudden onset of symptoms in two or more organ
systems: skin (e.g., acute urticaria, angioedema,
flush, mucosal edema), gastrointestinal tract (e.g.,
abdominal cramps, vomiting), respiratory tract
(e.g., dyspnea, wheezing, cough, stridor), or car-
diovascular system (e.g., decreased blood pressure,
collapse, incontinence) after contact with a likely
allergen or anaphylactic trigger
3. Drop in blood pressure after contact with an aller-
gen known to the patient or another anaphylaxis
trigger
Pharmacology of the most important drugs in
the treatment of anaphylaxis
The following substances have proven to be effective
in the pharmacological treatment of anaphylaxis.
Vasoactive substances
Adrenaline (epinephrine)
The most important drug in the acute treatment of
anaphylaxis is adrenaline (epinephrine) [75, 76]. By
activating alpha- and beta-receptors, adrenaline func-
tionally antagonizes all relevant pathomechanisms of
anaphylaxis via vasoconstriction, reduction of vas-
cular permeability, bronchodilatation, reduction of
edema, and positive inotropy of the heart. When
administered intravenously or intramuscularly, it has
the fastest onset of action of all anaphylaxis drugs.
In patients not requiring resuscitation, immediate
intramuscular administration of adrenaline at a dose
of 0.15–0.6mg to the outside of the upper thigh is the
pharmacological treatment of first choice. The risk of
severe cardiac side effects is considerably lower com-
pared to intravenous administration. In the absence
of an effect, and depending on adverse events, the
injection can be repeated every 5–10min subject to
clinical symptoms.
The subcutaneous injection of adrenaline is no
longer recommended due to its insufficient absorp-
tion and resulting delayed action.
If symptoms fail to stabilize and circulatory or
respiratory decompensation is imminent, adrenaline
should be given intravenously [77]. To this end, a di-
lution of 1mg adrenaline in 100ml NaCl 0.9%, i.e.,
a solution of 10µg/ml titrated with single boluses of
1µg/kg body weight (BW), is used under continuous
monitoring of circulatory parameters depending on
effects and side effects.
Electrocardiogram (ECG), pulse, and blood pres-
sure monitoring is required (see below for adrenaline
dosing in cardiac and circulatory arrest). In patients
receiving beta-adrenoceptor antagonist therapy and
failing to respond to several doses of adrenaline or
other vasoactive substances (see below), administra-
tion of glucagon is recommended since this has a pos-
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itive inotropic effect and leads to the up-regulation of
beta-adrenoreceptors on the cell surface [78]. How-
ever, glucagon only has an effect on cardiac symp-
toms.
In addition to its intramuscular administration,
adrenaline can also be given by inhalation in the
case of laryngeal edema and is also effective in bron-
chospasm. Here, the administration of adrenaline,
undiluted (e.g., 3–5ml at a concentration of 1mg/ml)
via a nebulizer using a breathing mask/mouthpiece
together with oxygen is recommended. The inhaled
administration of adrenaline does not replace par-
enteral administration and should only be used in an
additive capacity [58].
If bronchial obstruction is the major symptom, the
additional administration of inhaled beta-adrenocep-
tor agonists is effective, e.g., salbutamol, at an initial
dose of two puffs—if ineffective, between four and
eight puffs, and/or subcutaneous terbutaline. In the
case of young children, the efficacy of inhaling a dosed
aerosol can be increased by using a “spacer,” together
with a mask if required.
In the past, ephedrine was recommended instead
of adrenaline for hypotension during pregnancy.
However, the evidence for ephedrine is even more
scant than for adrenaline; therefore, in line with the
recommendations of other authors, the authors rec-
ommend the administration of adrenaline also in
anaphylaxis during pregnancy [79].
Even when administered appropriately, adrenaline
is not always effective and therapeutic failure or side
effects may be observed. The increase in cardiac
output results in increased oxygen consumption and
cardiac muscle necrosis. Adrenaline can also have
arrhythmogenic effects; therefore, in patients with
pre-existing coronary disease, intravenous adrenaline
may cause angina pectoris or myocardial infarction.
Although there is no absolute contraindication for
adrenaline in severe life-threatening anaphylaxis, the
indication should be carefully considered in patients
with cardiovascular disease. In the case of asystolic
cardiac arrest or pulseless electrical activity on ECG,
1mg i.v. adrenaline is given every 3–5min in adults or
0.01mg/kg in children [80, 81].
Other vasoactive substances
Dopamine, noradrenaline, and vasopressin are used
in the emergency setting by emergency physicians,
as well as under intensive care conditions using car-
diopulmonary motoring.
Dopamine Dopamine, which acts on alpha- and
beta-adrenoceptors and has a short half-life [82, 83],
is no longer used in German emergency and intensive
care medicine since it can elicit undesired tachycar-
dia and is markedly less effective in stabilizing blood
pressure than adrenaline or noradrenaline, which can
be well titrated with syringe drivers.
Noradrenaline Since noradrenaline is a highly po-
tent alpha- and somewhat less potent beta-1 adreno-
ceptor agonist and has a lower stimulatory potency at
the beta2-adrenoceptor compared to adrenaline, its
bronchodilatory effect is lower at therapeutic doses.
Therefore, its principal effect is an increase in periph-
eral resistance and systolic blood pressure. Its effect
on the lungs is comparatively small. Noradrenaline
is used particularly when volume replacement and
adrenaline have an insufficient effect [76, 84]. Due
to its marked vasoconstrictive effects, it should be
used only as a continuous intravenous infusion under
strict blood pressure and pulse monitoring. Dosage is
0.02–0.15µg/kg per minute.
Vasopressin The use of vasopressin in the treatment
of severe hypotension has been described by anes-
thetists [85].
There are individual reports on the successful use
of vasopressin in volume- and catecholamine-refrac-
tory shock. This is not an evidence-based treatment;
it is optional in extremely severe situations of per-
sistent shock when treatment with volume and other
catecholamines has failed. An effect on mortality or
duration of intensive care hospitalization could not be
shown for children. Dosage is 0.01–0.03 international
units (IU)/min.
Oxygen
In manifest cardiovascular or pulmonary reactions,
the administration of oxygen via a breathing mask is
recommended, in particular a non-rebreather mask.
The administration of high-flow oxygen (100%) is rec-
ommended. A laryngeal mask or tube may be helpful.
Only on rare occasions is tracheal intubation by an ex-
perienced physician (usually an emergency physician
or anesthetist) necessary. The reader is referred here
to the S1 guidelines for prehospital airway manage-
ment, which provide an algorithm explaining both the
indication for and the performance of invasive pre-
hospital airway management (Fig. 2; [58]).
Volume replacement
A major pathophysiologic aspect of anaphylaxis is the
resulting relative hypovolemia induced by vasodilata-
tion and capillary leakage [86]. As such, it is clear
that volume therapy can only be used in addition to
the crucial mast cell-stabilizing and vasoconstrictor
effect of adrenaline therapy [87–89]. This can only be
achieved with a large-lumen intravenous catheter. If it
is not possible to perform an intravenous injection, in-
traosseous access needs to be obtained. Anaphylactic
shock in adults requires rapid administration of a high
amount of volume: 1–3 l of balanced electrolyte solu-
tion depending on response. In children, 20ml/kg BW
are initially administered by hand as rapidly as possi-
ble. After re-evaluation, repeated boluses of 20ml/kg
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Fig. 2 Algorithm for prehospital airway management (from [58]). EGA epiglottic airway, ETI endotracheal intubation
are administered until hemodynamic stabilization is
achieved.
Gelatin and dextran solutions—despite their posi-
tive hemodynamic effects—should not be used in ana-
phylaxis due to their histamine-releasing potency and
their own risk of inducing anaphylaxis (e.g., in the case
of dextran without pretreatment with low molecular
hapten-dextran) [7].
According to the most recent evaluation by the Eu-
ropean Medicines Agency (EMA), hydroxyethyl starch
(HES) preparations are contraindicated in the criti-
cally ill [90–92]. Due to the lack of relevant literature,
the guideline group is somewhat reluctant to make
recommendations.
Antihistamines (histamine H1-receptor antagonists)
The central role of histamine as a mediator of aller-
gic reactions and the effect of histamine H1-receptor
antagonists in acute urticaria or rhinoconjunctivitis
are undisputed; however, their effects on circulation
and bronchoconstriction have not been demonstrated
[93]. Antihistamines have a slower onset of action
compared to adrenaline, but have a good benefit–risk
profile and a wide therapeutic window. One can as-
sume an effect on allergic reactions. Therefore, anti-
histamines should be given in all anaphylactic reac-
tions in order to antagonize the effect of histamine
as early on as at the initial stage, once vital functions
have been stabilized. Under no circumstances should
immediate life-saving measures such as intramuscu-
lar administration of adrenaline, volume replacement,
or oxygen administration be delayed by the use of an-
tihistamines!
In terms of intravenous administration in the
acute treatment of anaphylaxis, only the first-genera-
tion histamine H1-receptor antagonists dimetindene
(0.1mg/kg BW) and clemastine (0.05mg/kg BW), with
their well-known sedative side effects, are available.
At higher doses, antihistamines may show antimus-
carinic effects ranging from tachycardia, mouth dry-
ness, intestinal atony, urinary retention, increased
intraocular pressure to glaucoma attack and paradox-
ical states of arousal [94]. Therefore, these symptoms
need to be borne in mind.
Second-generation histamine H1-antagonists are
not approved as yet for the treatment of anaphylaxis
and are not available for intravenous injection; nev-
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ertheless, the newer, more selective histamine H1-
antagonists are often recommended as an oral treat-
ment, having shown rapid onset of action in placebo-
controlled skin test studies [93]. In the case of oral an-
tihistamine administration, the maximum approved
dose is primarily recommended. However, the expert
group agrees that higher doses (up to a maximum
of four times the approved single dose) can be given
in individual cases, as recommended in the treat-
ment of chronic urticaria [95]. Further studies with
newer H1-receptor antagonists for the treatment of
anaphylaxis are urgently required. In particular, in-
travenous preparations of modern non-sedating H1-
antihistamines would be desirable.
There is little evidence for an effect of histamine
H2-receptor antagonists in the treatment of acute
anaphylactic reactions. One study reports a reduc-
tion in cutaneous symptoms after the additional
administration of ranitidine compared with the use
of a histamine H1-receptor antagonists alone in the
treatment of allergic reactions [96]. There is somewhat
more evidence for the prevention of hypersensitivity
reactions by the addition of histamine H2-receptor
antagonists, although the effect was not evaluated
separately from other drugs [97, 98]. There are case
reports in the literature on anaphylactic reactions
caused by ranitidine [99]. The combined use of
histamine H1- and H2-receptor antagonists can be
attempted [100].
Glucocorticoids
Glucocorticoids plays a secondary role in the acute
phase of anaphylaxis due to their comparatively slow
onset of action [101].
There are no systematic clinical studies for this
indication. However, glucocorticoids are effective in
the treatment of asthma. A non-specific membrane-
stabilizing effect within 10–30min of administra-
tion of very high doses of glucocorticoids (in adults,
500–1000mg independent of the potency of the sub-
stance) has been postulated in review articles [4, 101,
102]. In the absence of intravenous access, gluco-
corticoids may also be given orally in syrup form
or rectally in suppository form, especially in small
children (e.g., prednisolone suppositories or rectal
enemas) at a dose of 2mg/kg.
In the case of slow response and unclear evidence,
treatment with glucocorticoids should only be per-
formed once vital functions have been stabilized
and immediate life-saving measures have been per-
formed, such as oxygen administration, intramuscular
adrenaline use, or volume substitution!
General aspects and treatment measures
When and how should allergen contact be stopped?
In the case of anaphylaxis, one should first establish
whether it is possible to stop further allergen expo-
sure. In particular situations (e.g., infusions), this can
be readily achieved and should be done immediately.
The use of a tourniquet on an extremity and/or sub-
cutaneous injection of adrenaline around a local aller-
gen depot (e.g., wasp sting or injection site of allergen-
specific immunotherapy) is no longer recommended,
since the therapeutic benefit is questionable and there
is a risk of distracting from more important measures.
Table 4 Emergency equipment for the treatment of ana-
phylactic reactions in the medical office
Stethoscope
Blood pressure monitor
Pulse oximeter, possibly also blood glucose meter
Tourniquet, venous catheters (in different sizes), syringes, infusion set,
adhesive tape for catheter fixation
Oxygen and nebulizer set with oxygen mask (different sizes)
Bag valve mask (different sizes)
Suction device
Guedel tube where appropriate
Volume for infusion (e.g., balanced electrolyte solution)
Drugs for injection: adrenaline, glucocorticoid, histamine H1-receptor antag-
onist
Short-acting beta2-adrenoceptor agonist, e.g., salbutamol for inhalation
(preferably as an inhalation solution for administration via a nebulizer set
with mask, if necessary in metered dose with, e.g., inhalation aid/spacer/
mask, autohaler)
Automated external defibrillator
Table 5 Five-second round for rapid evaluation of vital
parameters (from A. Bohn, Bundesverband Ärztliche Leiter
Rettungsdienst Deutschland (ÄLRD) (www.aelrd.de))
Five-second
round
Examination of vital signs (spontaneous movement)
A—Airway Muffled speech, swollen tongue
B—Breathing Evaluation of breathing (dyspnea, stridor, wheezing;
optional: auscultation, pulse oximetry)
C—Circulation Evaluation of recap time (preferably forehead or ster-
num)
Pulse (strength, frequency, regularity) and blood pres-
sure
D—Disability Consciousness, blood glucose measurement
E—Exposure Inspection of easily visible areas of skin areas and
mucous membranes, question patient regarding other
symptoms (e.g., nausea, vomiting, headache, feeling of
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Table 6 Alarm limit values for vital signsa




1–5 Years 6–14 Years >14 Years
Heart rate (/min) >160 >130 >120 >110
Blood pressure (systolic,
mmHg)
<50 <60 <60 <70
Respiratory rate (/min) >40 >35 >30 >25
Oxygen saturation (%) <92 <92 <92 <92
aThese values may vary due to high individual variability and can be re-
garded as guide values. Evidence-based data from clinical studies are not
available
Should one call for help?
If possible, further help should be called for in order
to achieve the conditions for adequate medical care.
All practice-based physicians should keep emergency
equipment available for the treatment of anaphylac-
tic reactions (Table 4). The team should be regularly
trained, with the option of designating tasks. In the
case of severe anaphylactic reactions, the emergency
services/paramedics should be alerted (in Germany,
call 112).
How should symptoms and complaints be recorded?
First of all, a short history should be taken and a basic
physical examination carried out. This comprises the
following steps summarized in a “five-second round”
(Table 5) (www.aelrd.de).
Alarm values for vital parameters are listed in Ta-
ble 6. These examinations need to be repeated over
the course of treatment at regular intervals.
Young children can be examined while held by
a parent. The initial aim is to calm the child and the
parents in order to create an adequate examination
and treatment environment. When small children are
restless, it may be difficult or impossible to examine
the oral cavity and perform lung auscultation. Caus-
ing irritation with a tongue depressor may increase
airway obstruction and should be avoided. In this
case, and in addition to general signs of dyspnea,
such as retraction of the thorax or the nasal wings,
attention should be paid to other clinical signs of up-
per respiratory tract obstruction, such as inspiratory
stridor or salivation, as well as lower airway obstruc-
tion with a prolonged expiratory phase and expiratory
stridor or wheezing.
How should severity be assessed?
Based on this examination, the degree of severity of
anaphylaxis should be evaluated and the most life-
threatening leading symptom identified. The most
life-threatening symptom needs to be treated first.
This leads to the six most common scenarios ([103];
Fig. 3):
1. Anaphylaxis with cardiovascular and/or respiratory
failure (grade IV anaphylaxis)
2. Anaphylaxis with a predominantly cardiovascular
reaction (grade II/III anaphylaxis)
3. Anaphylaxis with predominant upper airways ob-
struction (grade II/III anaphylaxis)
4. Anaphylaxis with predominant lower airways ob-
struction (grade II/III anaphylaxis)
5. Anaphylaxis with predominant gastrointestinal in-
volvement (grade II anaphylaxis)
6. Anaphylaxis with systemically mediated general-
ized skin manifestation and subjective symptoms
(grade I anaphylaxis).
How should the patient be positioned?
Immediately after examination, symptom-oriented
positioning of the patient needs to be carried out.
A flat position and avoidance of abrupt changes in
position (sitting up, standing up) or further physical
exertion (running) are a fundamental strategy. Posi-
tioning can vary according to the situation. Sitting/
standing up and physical exercise (running) should
be avoided due to abrupt volume shift (“venous col-
lapse”) or aggravation of anaphylaxis (co-factors). In
the case of impaired consciousness but intact circu-
lation, especially in preclinical situations, stable side-
positioning is recommended. To improve the hemo-
dynamic situation, Trendelenburg positioning (legs
up) can be performed. In situations where respiratory
distress is the leading symptom (dyspnea), a half-
sitting position may be better. When treating chil-
dren, care must be taken not to exert any force during
positioning that may increase the child’s anxiety.
How should anaphylaxis with cardiovascular arrest
be treated?
Cardiopulmonary resuscitation with chest compres-
sions and mouth-to-mouth breathing at a ratio of 30:2
(compressions:breaths) in adults should be initiated.
In children, resuscitation is initiated in line with the
current European Resuscitation Council (ERC) guide-
lines, i.e., after five initial breaths, two breaths are
given after every 15 chest compressions. An auto-
mated defibrillator should be used and early defibril-
lation performed in the case of ventricular fibrillation.
An intravenous or intraosseous catheter is required for
further drug treatment. Adrenaline (intravenous or in-
traosseous) at a dose of 1mg in adults or 0.01mg/kg
is the drug of first choice and is repeated in at 3- to
5-min intervals until stabilization of spontaneous cir-
culation has been achieved [80, 81]. For sufficient
oxygenation in emergency care, bag-valve-mask ven-
tilation with 100% oxygen is sufficient. If optimization
measures (positioning of the head, Guedel tube, two-
person technique) are unsuccessful in the case of dif-
ficulties with mask ventilation, supraglottic airway de-
vices are used. Laryngeal masks and laryngeal tubes
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Fig. 3 Acute treatment of
the most common anaphy-
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Table 7 Pharmacotherapy for children, adolescents, and adults under intensive care conditions
Substance Indication Route of administration Dose <15kg BW 15–30kg
BW


















(if i.m. not possi-
ble)
Titrating i.v./i.o. 1µg/kg 0.01ml/kg BW 0.01ml/kg BM 0.01ml/kg BW 0.1–0.6mg










– Inhaled via nebulizer – 3mlb 4mlb 5mlb 5mlb
Dimetindene – Intravenous 0.1mg/kg 1mlc 2–3mlc 4mlc 8mlc or
1ml/10kg BW
Prednisolone – Intravenous 2mg/ml 25mg 50mg 100mg 250–1000mg
Salbutamol
Terbutaline









Reproterold – Continuous infusion – 0.1µg/kg/min 0.1µg/kg/min 0.1µg/kg/min 0.1µg/kg/min





10–20ml/kg 10–20ml/kg 10–20ml/kg 500–1000ml
Oxygen – Nasal cannula
Non-rebreather mask
– 2–12 l/min 2–12 l/min 2–12 l/min 2–12 l/min
MDI metered-dose inhaler, Amp ampoule, BW body weight
aFor intravenous/intraosseous administration, 1ml of 1:1000 solution (= 1mg adrenaline in 1ml of commercial solution) with 9ml NaCl 0.9% (final concentration
1:10,000= 0.1mg/ml) or prefilled adrenaline syringe (1mg/10ml) are used
bFor intramuscular administration and inhalation, the undiluted commercially available solution is used (adrenaline 1:1000, 1mg/ml)
cOf a basic concentration for 1mg/ml (1ml contains 1mg dimetindene maleate)
dReproterol can also be given as a bolus
can be used in all age groups. Alternatively, a pharyn-
geal tube can be used in small children; here, ventila-
tion is induced via a nasal tube (tube length= tip of the
nose–ear tragus) while holding the mouth and other
nostril closed. Endotracheal intubation represents the
final method of airway management. This can also
be performed as a first step in the case of sufficient
expertise. It has been shown for all age groups that
endotracheal intubation should only be performed by
experienced individuals [58, 104].
For successful resuscitation, it is important to
compensate for the underlying volume deficiency
by means of forced volume replacement, according
to the pathophysiology of anaphylaxis. Immediate
transfer to and treatment on an intensive care unit
are recommended (Table 7).
How should anaphylaxis with a cardiovascular
reaction as the leading symptom be treated?
As an immediate measure, intramuscular (body
weight-adjusted) injection of adrenaline is recom-
mended, especially when there is no intravenous
catheter (Fig. 3; Table 7). In this situation, the
adrenaline auto-injectors used for layperson admin-
istration may be advantageous for their rapid usabil-
ity. Standardized doses of auto-injectors of 0.15mg,
0.3mg, or 0.5mg are practical single doses for ad-
ministration. In the case of insufficient response,
the intramuscular injection can be repeated after
5–10min.
Oxygen administration is recommended with the
aim of increasing the inspired oxygen fraction (FiO2)
to >0.5. This is possible with a non-rebreather oxygen
mask. Nasal tubes do not increase FiO2 sufficiently.
In all cases of impaired consciousness, vomiting
should be expected at any time. This needs to be
considered when positioning the patient. The mouth
should be opened using the Esmarch (jaw thrust) ma-
neuver and inspected for vomited material or foreign
bodies (e.g., dental prostheses). An operational suc-
tion unit is helpful.
An intravenous catheter is necessary for further
treatment (Table 7). If this is not possible, an in-
traosseous catheter is indicated. The central aim of
treatment is to compensate for the relative volume
loss. Forced volume replacement with a crystalloid
solution (balanced electrolyte solution) is required in
the form of a volume bolus over 5min. In adults,
500–1000ml are administered, while in children the
volume bolus is initially 20ml/kg. A flow rate of this
magnitude requires a large-lumen indwelling venous
catheter (≥18 gauge) or several catheters.
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Table 8 Pharmacotherapy for children, adolescents, and adults under non-intensive conditions (e.g., outpatient setting)
Substance Administration <7.5kg BW 7.5–25 (–30)d kg BW 30–60kg BW >60kg BW
Adrenaline Intramuscular 50–600μg
Adrenaline Auto-injector i.m. Not approved 150µg 300µg 1–2× 300µg or 500µg
Adrenaline Inhalation nebulizer 2–5mlb
Adrenaline Intravenousa Titrating bolus doses 1μg/kg BW
Dimetindene Intravenous 1mlc 1ml/10kg BWc
(max. 4ml)
1Amp= 4mlc 1–2 Amp= 4–8 mlc
(1ml/10kg BW)
Prednisolone Intravenous 50mg 100mg 250mg 500–1000mg
Salbutamol
Terbutaline
Inhaled 2 Puffs via spacer 2 Puffs via spacer 2–4 Puffs via spacer 2–4 Puffs via spacer
Volume Bolus (NaCl 0.9%) 20ml/kg BW 20ml/kg BW 10–20ml/kg BW 10–20ml/kg BW
Oxygen Inhaled 2–10 l/min 5–12 l/min 5–12 l/min 5–12 l/min
AMP ampoule, BW body weight
aFor intravenous administration, a 1-mg/ml adrenaline solution is diluted in 100ml NaCl 0.9% (final concentration, 10mg/ml)
bFor inhalation, the original concentration of the commercial solution is used (1mg/ml)
cAn original concentration of 1mg/ml (1ml contains 1mg dimetindene maleate)
dVarious weight-dependent approvals for different auto-injectors
In persistent or life-threatening shock, fractionated
intravenous/intraosseous or intramuscular adminis-
tration of adrenaline or as a continuous drip is indi-
cated. Antiallergic drugs like histamine H1-receptor
antagonists (note: antimuscarinic side-effects of se-
dating anthistamines!) or glucocorticoids should be
used after stabilization of vital functions and adminis-
tration of i.m. adrenaline (Table 7). Continuous blood
pressure and pulse monitoring is indicated in these
situations. With adequate expertise, other sympath-
omimetic drugs such as noradrenaline may be used
or a continuous infusion initiated with pumps under
continuous monitoring.
How should anaphylaxis with upper airway
obstruction as the leading symptom be treated?
Clinically detectable swelling in the area of the upper
airways is characteristic for this situation. This may
be identifiable as swelling of the tongue or uvula, dys-
phonia, or inspiratory stridor. These situations can
become life-threatening if the laryngeal entrance is
obstructed. As an immediate measure, intramuscu-
lar injection of adrenaline and oxygen administration
are recommended (Fig. 3). Additional inhalation of
adrenaline is also indicated in such situations (Ta-
bles 7 and 8). If the treatment response is insuffi-
cient, airway management according to the algorithm
in the S1 guideline for prehospital airway manage-
ment should be performed (Fig. 2; [58]).
How should anaphylaxis with bronchial obstruction
as the leading symptom be treated?
This symptom is one of the most common in ana-
phylaxis. In all potentially life-threatening situations,
adrenaline should be given intramuscularly. Topi-
cal bronchodilator therapy is of central importance
([105]; Fig. 3). Various short-acting beta-adrenoceptor
agonists (e.g., salbutamol, terbutaline) are approved
for the treatment of bronchial obstruction (Tables 7
and 8). It is important to note that patients with ana-
phylaxis often have little experience with inhalation
therapy and can more easily use spacers for metered
dose inhalers or procedures with continuous aerosol
administration (such as masks for pressure/oxygen
connection and electric nebulizers). This also holds
true for young children and children without experi-
ence with inhalation therapy. Compact battery-driven
nebulizers are now available and can also be used in
emergency preclinical situations. If therapy needs
to be escalated, repeated i.m. adrenaline is given.
If resuscitation is imminent, intravenous adminis-
tration of adrenaline can be considered. A further
treatment modality is the application of an injectable
beta2-adrenoceptor agonist (e.g., terbutaline s.c. or
reproterole i.v.) (Table 7).
In acute severe asthma with muscular exhaustion
and failure of non-invasive ventilation, emergency
anesthesia with invasive ventilation may be necessary
[65]. Here, the current guidelines and recommenda-
tions on anesthesia with esketamine and midazolam
should be followed [104].
How should anaphylaxis with predominantly
abdominal symptoms be treated?
Anaphylaxis with predominantly abdominal symp-
toms is treated in the same way as anaphylaxis with
generalized skin symptoms (Fig. 3). Only if there
is insufficient response to systemically administered
antiallergic drugs will gastrointestinal symptoms be
treated separately. Nausea, vomiting, or abdominal
cramps may be the relevant symptoms. Antiemet-
ics such as metoclopramide, antihistamines (e.g.,
dimenhydrinate) or serotonin-[5-HT3] antagonists
(e.g., ondansetron) can be used for treatment. For
abdominal cramps, intravenous administration of
a muscarinic receptor antagonist (butylscopolamine)
may be considered.
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How should anaphylaxis with predominantly skin
symptoms be treated?
Placing an intravenous catheter is the first measure
taken. A crystalloid solution drip (e.g., balanced elec-
trolyte solution) is recommended to keep this open.
Antiallergic drugs such as dimetindene or glucocorti-
coids are applied at usual doses (Fig. 3; Table 8).
Special aspects of hospital treatment
Which emergency drugs should be stored in the
emergency department or on the ward?
In emergency departments and on wards where
provocation tests or allergy procedures with in-
creased risk for anaphylaxis are performed, up to two
adrenaline auto-injectors each in the doses 300μg or
500μg should be kept available. If the treatment of
children is expected, a further two 150-µg adrenaline
auto-injectors must be kept available. Adrenaline
inhalation using a nebulizer should be available. In
addition, injectable histamine H1-receptor antago-
nists and glucocorticoids, as well as salbutamol for
inhalation with appropriate devices (spacer or moist
inhalation), should be on hand.
How should patients with acute anaphylaxis be
treated in the emergency department?
Individuals presenting to the emergency department
with suspected anaphylaxis need to be treated im-
mediately. In order to make the diagnosis of “ana-
phylaxis,” the clinical criteria need to be applied
(see above). In addition to an immediate evaluation
of clinical signs and symptoms (Fig. 3), continuous
monitoring of circulation, including measurement of
pulse, blood pressure, and peripheral oxygen via pulse
oximetry, must be established. Patients with severe
anaphylactic reactions (e.g., requiring an adrenaline
auto-injector) should be hospitalized and supervised
for 24h due to the risk of a biphasic (bimodal) reac-
tion.
How should anaphylaxis be treated on the ward?
Elicitors of anaphylaxis on the ward are often drugs
used there for treatment. Reactions to parenterally
administered substances occur rapidly after use. In
the case of substances for enteral administration,
delayed symptoms are also possible. The first mea-
sure to be taken is to discontinue allergen exposure
and—depending on the grade of severity—alert the
emergency team.
What are the special considerations for planned
provocation testing in anaphylaxis?
Whenever a procedure that carries a risk of anaphy-
laxis is planned (allergy provocation test, allergen-
specific immunotherapy with hymenoptera venom),
careful preparation is essential, including:
 Monitoring sheet with emergency medication and
emergency plan.
 Emergencydrugs prepared inweight-adjusted doses
near to the patient.
 Rapid medical care if allergic symptoms occur.
 Intravenous catheters for rapid administration of
intravenous drugs and volume.
 The indication to administer medication is estab-
lished according to the flow diagram (Fig. 3).
It is advisable that affected patients or, in the case of
young children, their parents learn to use the auto-in-
jector themselves under close instruction from med-
ical personnel in order to train for administration at
home. If possible, training should be with the same
type of auto-injector as the one that will be used by
the patient. This approach enables patients to gain
confidence in administering an auto-injector and re-
duce the fear associated with its use.
How should anaphylaxis be treated on the intensive
care unit?
One advantage of high care (on an intensive care unit)
with continuous monitoring is that shock states can
be detected and treated earlier. If the intensive care
personnel become aware of anaphylaxis, whether due
to hypotension, tachycardia, a warning signal from
the monitor, or low oxygen saturation, the principal
procedure does not differ from other settings. Com-
mon elicitors of anaphylaxis on an intensive care unit
include drugs and blood products; therefore, the very
first measure to take is to discontinue administra-
tion of the potential allergen or elicitor. The priority-
oriented ABCDE (airway, breathing, circulation, dis-
ability, and exposure) approach (Table 5) described
above is then initiated. Depending on the ongoing
mode of intravenous catecholamine treatment, sy-
ringe pumps may need to be adapted. Adrenaline
should be given due to its mast-cell stabilizing action,
which is unique among catecholamines. One needs
to bear in mind that, under continuous vasopressor
treatment, the normal intramuscular administration
of 0.3–0.5mg adrenaline may have reduced efficacy
due to peripheral hypoperfusion. Therefore, intra-
venous administration in intensive care is performed
in 50μg bolus doses in adults and 1μg/kg bolus doses
in children [81] until the patient is stabilized, prefer-
ably via a central venous catheter; alternatively, pe-
ripheral administration is also possible.
14 Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update K
guidelines
What needs to be considered in discharge
management after an anaphylactic reaction?
Following successful treatment of anaphylaxis, pa-
tients, and/or their relatives where appropriate,
should be informed about the condition and undergo
adequate allergy diagnostics (Table 8). If anaphylaxis
occurred intraoperatively, an anesthesia document
needs to be issued and the patients must be informed
about the reaction. It is absolutely essential to docu-
ment reactions, together with symptoms, co-factors,
and possible elicitors. An emergency first-aid kit is
prescribed (see below).
Patients with food allergies should receive an in-
dividually tailored therapeutic elimination diet under
the guidance of a nutritionist with allergy expertise (in
Germany, the addresses of certified specialists can be
obtained from the German Allergy and Asthma Asso-
ciation [Deutscher Allergie- und Asthmabund, DAAB]
and the working group on dietetics in allergology [Ar-
beitskreis Diätetik in der Allergologie]). Following reac-
tions to insect stings, the possibility of allergen-spe-
cific immunotherapy should be discussed.
If the elicitor of anaphylaxis with extracutaneous
symptoms cannot be reliably avoided (e.g., insect
stings, foods) or there is an increased anaphylaxis
risk, patients should be advised to carry an emer-
gency first-aid kit with them at all times, together
with a written document, e.g., anaphylaxis passport
(see section below on patient management and self-
medication). The patient should receive instructions
regarding emergency management and the use of
emergency medication. If the elicitor is a drug used
in the hospital setting, an allergy passport should be
provided with detailed documentation of the reaction
in order to allow allergy diagnostics. In the case of
recurrent reactions, an attempt at long-term pharma-
cological treatment can be considered, such as long-
term administration of antihistamines or an anti-IgE
antibody such as omalizumab [106, 107].
For questions regarding everyday management,
particularly in food-induced anaphylaxis, patients
should be referred to a patient organization for sup-
port (e.g., in Germany, the DAAB).
How should perioperative anaphylaxis be managed?
During analgosedation or general anesthesia, the pa-
tient is not able to communicate early symptoms such
as itch or nausea; therefore, continuous supervision
and observation of respiratory and cardiovascular
function is important. If unexpected hypotension or
tachycardia occur in the perioperative setting, other
possible symptoms of anaphylaxis need to be imme-
diately sought:
– Is erythema, swelling, or urticaria developing, pos-
sibly beginning on the arm receiving the infusion?
– Is there prolonged expiration with reduced expira-
tory flow or a decrease in pulse oximetry oxygen sat-
uration?
– Is there decreased lung compliance?
The differential diagnosis in the context of viscerosur-
gical procedures needs to differentiate eventeration
syndrome, which may manifest clinically as prostacy-
clin-mediated flushing, tachycardia, and hypotension.
If the working diagnosis severe anaphylaxis or
anaphylactic shock is confirmed, treatment with
adrenaline is immediately initiated. In adults with
severe shock but maintained circulation, titrated
adrenaline in 0.1- to 0.3-mg bolus doses is adminis-
tered until systolic blood pressure rises to 100mmHg.
At the same time, volume therapy is initiated with
1–3 l of balanced electrolyte solution. Histamine H1-
receptor antagonists and optionally H2-antagonists
and glucocorticoids, as described above, are then
administered intravenously. Extended hemodynamic
monitoring should be considered. If these measures
are able to stabilize the patient, one needs to decide
whether and to what extent the surgical procedure
can be performed or continued. Further intensive
monitoring is recommended depending on severity.
What are the special aspects of treatment in the
medical office?
Which elicitors of anaphylaxis are common in the
medical office?
Possible elicitors in the medical office include aller-
gen solutions used in allergen-specific immunother-
apy (hyposensitization), as well as natural rubber la-
tex, local anesthetics, and drugs used in the medical
office (e.g., antibiotics, cyclooxygenase inhibitors, ra-
diographic contrast media, vaccines, and intravenous
iron). Furthermore, patients with severe allergic reac-
tions to hymenoptera venoms or foods may present
to the nearest medical office.
How should a medical office prepare for emergency
treatment?
All medical offices should keep emergency equipment
available for the treatment of anaphylaxis. Since ana-
phylactic reactions are not a regular occurrence in
most medical offices, regular training in anaphylaxis
recognition, as well as pharmacological and non-
pharmacological treatment, needs to be performed
(especially with regard to distribution of tasks, posi-
tioning, calling for help, oxygen, recording respiratory
and cardiovascular function). Regular training of
team procedures during anaphylaxis improves medi-
cal care in the emergency situation. A written, easily
accessible emergency plan with a description of the
necessary drugs and dosages is highly recommended.
Patients should be treated in a room separated from
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other patients yet easily accessible to several care-
givers. In the pediatric setting, the weight-adjusted
dosages for emergency therapy in children with aller-
gen-specific immunotherapy can already be noted on
the documentation sheet.
It is helpful to define the following specifications in
preparation for an emergency situation:
 Where is the emergency equipment stored?
 What is the exact procedure in an emergency?
 Who is responsible for what? (inform the physician,
take care of the patient, call for help, etc.)
 In which roomwill the patient be treated?
What emergency equipment should a medical office
keep available?
The elements shown in Table 4 are recommended as
emergency equipment in a medical office. A pulse
oximeter should be available, whereas ECG and blood
pressure monitors are not standard equipment in all
medical offices.
What is the procedure in an emergency?
Acute treatment is performed as described above
(treatment in the hospital) with no essential differ-
ences.
Adrenaline is also administered in the medical of-
fice by physicians not experienced in emergency treat-
ment, preferably intramuscularly. Administration can
be repeated if circulation is not stabilized. If there
is no monitor, heart rate and blood pressure can be
measured, while the capillary refill time on the skin of
Table 9 Important aspects of discharge management of
anaphylaxis patients
Allergy historyIdentification of the
elicitor If necessary, referral to allergy diagnostics (specific
IgE and/or skin test)
In food allergy: individually tailored therapeutic
elimination diet (patient organizations, e.g., DAAB,
“dietetics in allergy” working group, German Society
for Nutritional Medicine)
In insect venom allergy: consider indication for
allergen-specific immunotherapy
Recommendations
for the prevention of
renewed reactions
In drug allergy: avoidance and allergy passport
recommended
Written plan for pharmacological self-management
(anaphylaxis passport)






Information on support from patient organizations
for problems in childcare facilities, school, shopping,
travelling




Information on and referral to specialized allergy-
trained nutritionists
DAAB German Allergy and Asthma Association (Deutscher Allergie- und
Asthmabund)
the sternum or fingertip can provide information on
cardiovascular function.
Caution should be taken with the intravenous ad-
ministration of adrenaline; this should be reserved
for physicians with expertise and requires continuous
blood pressure and pulse monitoring (exception: re-
suscitation situation with an i.v. catheter already in
place).
In the case of anaphylaxis with medium to se-
vere involvement of the respiratory or cardiovascular
system, the emergency medical and rescue services
should be promptly alerted following discontinuation
of allergen exposure (in Germany, call 112).
How is discharge managed in the medical office?
Since the possibilities for patient monitoring are lim-
ited in the medical office, transfer to a hospital for
monitoring is recommended in the case of severe or
not reliably classifiable anaphylaxis. Otherwise, dis-
charge management is the same as from hospital, as
listed above (Table 9).
Special aspects in childhood
With regard to the dosing of certain drugs used in
the treatment of anaphylaxis, the special dosages for
children need to be taken into account.
Table 10 Indications for the prescription of an adrenaline
auto-injector
Patients with systemic allergic reactions and bronchial asthma (even with
no history of anaphylaxis)
Progressive severity of symptoms of the systemic allergic reaction
History of prior anaphylactic reactions to elicitors that cannot be reliably
avoided
Systemic allergy with extracutaneous symptoms to potent allergens such as
peanuts, tree nuts, milk, sesame
Strong sensitization with increased risk of anaphylaxis—prior to allergy
provocation testing
Patients that react to minute amounts of allergen
Adults with mastocytosis (also without known anaphylaxis)
Table 11 Indications for the prescription of an additional
(second) adrenaline auto-injector
History of extremely severe anaphylaxis
Obesity >100kg BW
Uncontrolled bronchial asthma
Nearest emergency medical care is poorly accessible
Especially high risk for severe anaphylaxis (e.g., adults with mastocytosis
after anaphylaxis)
Organizational: second auto-injector for childcare facility, school, or depend-
ing on the family situation
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Patient management and self-medication
Target groups for the prescription of an emergency
first-aid kit, including an adrenaline auto-injector
Indications for the prescription of an emergency first-
aid kit, including an adrenaline auto-injector, are
listed in Tables 10 and 11.
We recommend that all patients with:
1. A history of anaphylaxis
2. Systemic allergic reactions with extracutaneous
symptoms and high future risk of anaphylaxis (e.g.,
due to well-known potent allergens such as peanut,
tree nuts,milk, sesame) or at high risk for life-threat-
ening reactions (e.g., bronchial asthma)
3. Highly sensitized personswithout previous anaphy-
lactic reactions but high-grade suspicion of an in-
creased anaphylaxis risk—prior to allergy provoca-
tion testing
be provided with an emergency first-aid kit if the elic-
itor cannot be reliably avoided, as in the case of, e.g.,
insect venom or food anaphylaxis. The precise in-
dications are given in more detail in Table 10. It is
normally possible to avoid an elicitor in the case of
drug-induced anaphylaxis following adequate allergy
diagnostics, education, and the issuing of an allergy
passport.
Can an emergency first-aid kit also be prescribed in
patients with high-grade suspicion for anaphylaxis
prior to allergy testing?
Children with atopic eczema (atopic dermatitis,
eczema) are often sensitized to common food al-
lergens, especially after early onset severe eczema
[108, 109]. In the case of clinically relevant sensitiza-
tions, these patients often experience an anaphylactic
reaction after first oral exposure. In order to evaluate
the clinical relevance of this, an oral food challenge
is performed, often in the inpatient setting [110].
Since there is often an interval of several weeks or
months between the time of indication and the per-
formance of oral challenge tests, patients can be given
an adrenaline auto-injector in the interim. Instruc-
tion for use with the help of an auto-injector trainer
(“dummy”) is essential. When considering the ratio-
nale for this approach, one needs to consider the time
interval until oral challenge testing, the likelihood of
a clinically relevant food allergy, and the probable
severity of a reaction depending on concomitant dis-
eases such as asthma, as well as the likelihood of
accidental exposure.
In peanut or tree nut allergy, the risk of a systemic
reaction increases with the concentration of allergen-
specific IgE antibodies against storage proteins [109,
111]. The best predictor of clinical relevance is specific
IgE against the 2S albumins (Ara h 2 in peanut, Cor
a 14 in hazelnut, and Ana o 3 in cashew). In some pa-
Table 12 Contents of an emergency first-aid kit for pa-
tients with anaphylaxis
Auto-injector for intramuscular, body weight-adjusted ad-
ministration
>7.5 to 25kg BW or
>15–30kg BW:
150μga








Depending on patient age and preference, orally as fluid
or (lozenge) tablet. The dose of the non-sedating antihis-
tamine may be increased up to four times a single dose.
For dimetindene drops, weight-adjusted dose, as with the
intravenous formulation, can also be recommended as an
oral dose (see Table 8)
Glucocorticoid According to patient age and preference, oral (liquid or
tablet) or rectal with 50–100mg prednisolone equivalent
BW body weight
In known bronchial asthma or previous reaction with bronchospasm: addi-
tionally a beta2-adrenoceptor agonist
If severe obstruction of the upper airways is expected (laryngeal edema),
additionally an inhaled adrenaline preparation with spray head for pharma-
ceutical vials (needs to be specially requested from the pharmacist)
Note: An emergency first-aid kit should include an anaphylaxis passport
with written instructions on how to use the contents
aApproval differs for each auto-injector preparation
tients, 2S albumin-specific IgE is so high that one can
assume with 90–95% probability that these patients
will suffer an anaphylactic reaction even though they
have never have eaten this food allergen before [109,
111]. Oral food challenges are often not performed in
these patients, or only at a later point in time (e.g., at
the time of school entrance). These patients can be di-
agnosed with “high-grade suspicion” of, e.g., peanut
or tree nut allergy without ever having experienced
a clinical reaction. These patients should also receive
an adrenaline auto-injector, as well as therapeutic nu-
trition counselling in order to consistently avoid the
highly suspected foods and, where necessary, replace
nutrients lacking in their avoidance diet.
What should the emergency first-aid kit contain?
In German-speaking countries, physicians often pre-
scribe several drugs for patients to be put together in
an emergency first-aid kit, which should be carried
at all times together with the anaphylaxis passport.
The authors recommend an adrenaline auto-injector,
a histamine H1-receptor antagonist, a glucocorticoid,
and, in patients with bronchial asthma or a prior re-
action with bronchospasm, an inhaled bronchodilator
(beta2-adrenoceptor agonist) (Table 12).
When selecting the histamine H1-receptor antag-
onist, swallowing ability and individual preference
in terms of form of administration should be taken
into consideration (drops for small children, tablets
or lozenges for older children and adults). If there
is a history of difficulty in swallowing (e.g., laryngeal
edema), administration in liquid form is preferred.
The same criteria apply to glucocorticoids (1–2mg/kg
BW), whereby rectal administration is also possible.
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The expert group recommends the treatment of ana-
phylaxis with antihistamines in increased doses (up
to four times the approved single dose). The new
second-generation selective histamine H1-receptor
antagonists are not approved for the treatment of
anaphylaxis; however, they can be recommended
alongside sedating antihistamines for oral emergency
treatment, since they have shown a rapid onset of ac-
tion in placebo-controlled skin test studies and fewer
side effects, such as sedation. For asthma patients,
inhaled beta2-adrenoceptor agonists are additionally
prescribed. Alternatively, in the case of a prior history
of laryngeal edema, an adrenaline preparation for
inhalation may be prescribed.
There are various commercially available adrenaline
auto-injectors that differ in dose, handling, injection
mechanism, and needle length. Special instruction is
necessary, the preparations cannot be easily substi-
tuted, and repeat prescriptions need to be organized
[112]. The “aut idem” box needs to be ticked on the
prescription.
When should two adrenaline auto-injectors be
prescribed?
Table 11 shows a list of indications in which two
adrenaline auto-injectors should be prescribed.
The dosing of adrenaline for self-management in
anaphylaxis is a less controlled initial measure and
does not need to be the same as adrenaline admin-
istration under medical supervision and appropriate
monitoring. Due to a lack of data, dose recommen-
dations for self-management are given for children
in approximate relation to body weight, but are not
calculated directly from body weight in adults [113].
There is scant evidence on the optimal adrenaline
dose or number of adrenaline auto-injectors required
for self-management. There are cases in which physi-
cians or patients feel it necessary to prescribe a sec-
ond adrenaline auto-injector. Co-existing bronchial
asthma is a well-known risk factor for use of a sec-
ond adrenaline injector. The authors recommend pre-
scribing a second adrenaline auto-injector for the in-
dications listed in Table 11.
It is important to ensure that patients are pre-
scribed a second auto-injector, or replacement auto-
injector, that uses the same technique as their previ-
ous device. Patients should carry their emergency first
aid kit for immediate first aid with them at all times.
From an organizational perspective, it makes sense
in individual cases to prescribe two adrenaline auto-
injectors for different locations (e.g., school, childcare
facility, workplace, and in the case of separated par-
ents). However, this can lead to confusion and lack of
protection compared to patients that have their auto-
injector on them at all times. Therefore, the group
recommends the prescription of a single auto-injector
to be carried at all times.
When is an adrenaline auto-injector no longer
indicated?
An expert group of the European Academy of Allergy
and Clinical Immunology (EAACI) has intensively ad-
dressed the topic of the need for patients with insect
venom allergy to carry emergency self-medication
at all times [114] and has formulated recommenda-
tions on the prescription of adrenaline auto-injectors,
which have been included in the current guidelines
for the treatment of insect venom allergy [46]. Accord-
ing to these recommendations, the prescription of an
adrenaline auto-injector is no longer necessary when
the risk of a renewed systemic reaction is approxi-
mately comparable to that of the normal population.
This can be assumed after successful immunotherapy
and a well-tolerated sting reaction—either after a field
sting or after a sting challenge.
After completion of allergen-specific immunother-
apy, adrenaline auto-injector prescription is no longer
necessary in patients with only cutaneous/mucosal
symptoms (grade I) or in patients that have reacted
with more than cutaneous symptoms (grade II), but
have no additional risk factors for non-response to
venom immunotherapy [114]. Risk factors include
severe insect sting reaction (grade III or IV), bee
venom allergy, high risk of exposure (e.g., bee-keeper),
a systemic response under immunotherapy, mast cell
disease, elevated basal serum tryptase, and treat-
ment with ACE inhibitors. Whether the auto-injector
can be dispensed with once the maintenance dose of
venom immunotherapy has been reached is discussed
controversially. Between 70 and 80% of experts felt
that patients with only cutaneous/mucosal symptoms
(grade I) would not need an auto-injector once the
maintenance dose had been reached. Table 10 lists
indications for the prescription of adrenaline auto-
injectors.
What should training with the emergency first-aid kit
include?
Most anaphylactic emergencies occur in the course of
everyday life, often at home. Therefore, training on
emergency self-management should cover all mea-
sures that patients need to consider or take them-
selves in the case of a (renewed) emergency situation.
The patient should be instructed on how to:
1. Recognize anaphylactic reactions
2. Administer symptom-related self-medication
3. Store drugs correctly
4. Make an emergency call for help (in Germany and
Austria, call 112, in Switzerland, 144; report anaphy-
laxis/anaphylactic shock, follow telephone instruc-
tions given by the rescue center)
Potential elicitors (foods, insects, drugs) should be
preserved if possible.
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Known elicitors of anaphylaxis
Asthma?
  yes (yes, increased risk for severe reaction)
In case of emergency please notify: Name, Tel. No.
Where is the emergency set for immediate help stored?
 Empowerment of parents to apply drugs
Issued by
date, signature
Handling of adrenalin autoinjector
Signs of beginning reaction
Skin:
• Wheals, redness
• swelling of lips and face
• Itch (palms, soles, genital area)
or
Gastrointestinal:
• Nausea, vomitus, cramps, diarrhea
• Prickling in the mouth and throat
Others: 
• Runny nose / Anxiety / Vertigo
First aid
1. Stay with patient/child
emergency call 112
2. Antihistamine and cortisone
name  and amount
name  and amount
3. Adrenalin autoinjector prepared and watch 
Patient for signs of anaphylaxis
Signs of severe reaction
Airway:
• Sudden hoarseness, cough wheezing, 
dyspnea
Cardiovascular: 
• Blood pressure loss, loss of conscience
First Aid
 Concomitant or subsequent occurrence
of symptoms in different organs:
Skin / Gastrointestinal / Airways / cardiovascular
 Each reaction after
(eg wasp sting, cow’s milk, …)
societies involved
1. Adrenalin autoinjector into the lateral part 
of upper thigh muscle
name of adrenalin autoinjector
2. Positioning
with dyspnea: sitting
with cardiovascular symptoms: flat
with unconsciousness: stable side positioning
3. With dyspnea additional airway spray
name
4. Call paramedic or emergency physician (112)
5. Notify contact of patient
6. Additional application of antihistamine and 
    glucocorticoid (see above)
In case of doubt: Apply adrenalin autoinjector!
place for sticker of respective preparation 
Fig. 4 Anaphylaxis emergency plan
K Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update 19
guidelines
Self-medication is given according to symptoms
and the degree of certainty that allergen contact has
occurred: the correct stage-appropriate administra-
tion of a number of drugs for acute medication is
an essential part of patient information, since the
highest degree of uncertainty is found in this regard
among patients and their families. If it is certain that
contact with an anaphylaxis elicitor has taken place
(insect sting without successful allergen-specific im-
munotherapy, eating allergy-eliciting food, use of an
allergy-eliciting drug), the anaphylaxis emergency
plan needs to be followed (Fig. 4). The emergency
plan and anaphylaxis passport are important aids
that the allergy sufferer should have on them at all
times.
All patients with a history of anaphylaxis or their
relatives/guardians should receive individual instruc-
tion, including a practical demonstration of how to
handle the emergency kit, at the time of prescribing.
This training includes: information about the
elicitors of anaphylaxis, their avoidance, referral to
a nutritionist with allergy experience for advice on
a therapeutic elimination diet in the case of food-
induced anaphylaxis, the symptoms of anaphylaxis,
as well theoretical and practical knowledge (including
a demonstration) on how to administer emergency
drugs in the event of a renewed anaphylactic episode.
These instructions should be repeated with each new
prescription of an adrenaline auto-injector. The pa-
tient, as well as those in their social environment,
especially care-takers of children, also need to be in-
structed in the use of self-medication. Standardized
anaphylaxis emergency plans are available to this end
(Fig. 4), as are anaphylaxis documents and recom-
mendations for emergency management in childcare
facilities and schools. A summary of self-management
instructions is also given in the anaphylaxis passport,
which, in addition to triggers, includes drug dosage
and mode of administration depending on the clinical
symptoms.
Who should receive anaphylaxis group education?
Anaphylaxis group education is recommended for all
patients at high risk for renewed anaphylaxis. In addi-
tion to the mandatory individual instruction with the
emergency first-aid kit, the German working group on
anaphylaxis training and education (Arbeitsgemein-
schaft Anaphylaxie Training und Edukation, AGATE)
has developed an outpatient educational program.
The program (consisting of individual educational
units, 2× 3h), uses a target-oriented and self-con-
tained concept comprising written, standardized, and
interdisciplinary components for patients with ana-
phylaxis and carers of children and adolescents (e.g.,
parents), including a manual, documentation for par-
ticipants, and sample time schedules [113, 115]. The
educational program focuses on practical aspects
of self-management, including role-playing, e.g., on
handling adrenaline auto-injectors, as well as allergen
avoidance strategies, behavior in high-risk situations
in everyday life, and possibilities of risk manage-
ment. It is often necessary to individualize training to
address well-known individual problems and expec-
tations. The authors recommend anaphylaxis group
training whenever available. At present, anaphylaxis
training programs are generally not reimbursed by
insurances and hence not available in all regions of
Germany.
Where can one find further aids for the everyday
management of anaphylaxis?
In addition to standardized written anaphylaxis emer-
gency plans and the anaphylaxis passport, other in-
formation materials (such as brochures, shopping
guides, restaurant maps with information on specific
food allergies for the kitchen, documents for air travel,
etc.) can be made available by patient organizations
(in Germany, e.g., the DAAB). These organizations
also provide support in everyday management (Ta-
ble 9).
Adrenaline auto-injection trainers and training ma-
terial are also available from the manufacturers of
adrenaline auto-injectors, as well as from the DAAB.
Further aids (bags for the emergency kit, as well as
stickers or clothing with warning messages) can be
ordered via patient organizations or the internet. SOS
emergency bracelets or capsules are not yet popular
in German-speaking countries and often go unnoticed
in emergency situations.
It seems important to involve not only affected pa-
tients and their social environment (e.g., parents), but
also physicians active in the field of allergy and ana-
phylaxis management, as well as other occupational
groups such as paramedics, emergency services, hos-
pital emergency departments, organizers of first aid
courses, and patient organizations [116].
Overall, the acute management of anaphylaxis
patients in Germany can be positively evaluated;
however, there are still considerable problems in
long-term management, e.g., in children in daycare
centers and schools, as well as shortcomings in the
prompt administration of adrenaline, further diag-
nostics, training, and education [28, 75].
It is important to make the medical profession
aware of this potentially life-threatening problem and
familiarize them with the possibility of intramuscu-
lar adrenaline administration, including the use of
adrenaline auto-injectors for self-medication.
Anaphylaxis after COVID-19 vaccination
Recently vaccination programs against COVID-19
have been started in several countries. Rare cases
of severe allergic reactions have been reported from
United Kingdom and USA; this has led to unset-
tledness and fear among patients and vaccinating
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physicians. The guideline group and allergological
societies therefore developed position statements
[117, 118] stressing the fact that some patients with
defined allergic conditions may be at increased risk
for anaphylaxis after COVID-19 vaccination, espe-
cially patients with severe allergic reactions to drugs
or vaccines as well as known hypersensitivities to
ingredients of the respective vaccines. In unclear
cases allergy diagnostics should be performed prior
to COVID-19 vaccination; also patients should be ob-
served over 30 minutes after vaccine injection. Physi-
cians and health personel involved in vaccination
centers should be aware of possible risks of anaphy-
laxis and the necessary acute treatment modalities
[117, 118].
Addendum
Production of the text
Following a decision of the board of the German So-
ciety for Allergy and Immunology (DGAKI) in 2017,
the “anaphylaxis” working group was asked to up-
date the text of the present guidelines together with
other scientific societies and experts from other areas.
In addition to allergology, these experts come from
anesthesiology and intensive medicine, dermatology,
pediatrics, internal medicine, pulmonology, otolaryn-
gology, psychosomatics, pharmacology, emergency
medicine, and theoretical surgery.
Allergy societies in Austria and Switzerland, as well
as representatives of patient organizations, have also
participated.
In addition to members of the DGAKI, represen-
tatives of the Society of practicing allergists (Ärzte-
verband Deutscher Allergologen, AeDA), Society for
pediatric allergology and environmental medicine
(Gesellschaft für pädiatrische Allergologie undUmwelt-
medizin, GPA), College of children and adolescents
physicians in Germany (Berufsverband der Kinder-
und Jugendärzte Deutschlands, BVKJ), Society for
neonatology and pediatric intensive medicine (Gesell-
schaft fürNeonatologie und pädiatrische Intensivmedi-
zin, GNDPI), German Academy for Allergology and
Environmental medicine (Deutsche Akademie für Al-
lergologe und Umweltmedizin, DAAU), Austrian Soci-
ety for Allergology and Immunology (Österreichis-
che Gesellschaft für Allergologie und Immunologie,
ÖGAI), Swiss Society for Allergology and Immunol-
ogy (Schweizerische Gesellschaft für Allergologie und
Immunologie, SGAI), German Society for Anesthesi-
ology and Intensive Medicine (Deutsche Gesellschaft
für Anästhesiologie und Intensivmedizin, DGAI), Ger-
man Society for Pharmacology (Deutsche Gesellschaft
für Pharmakologie, DGP), Working group anaphylaxis
training and education (Arbeitsgemeinschaft Anaphy-
laxie Training und Edukation, AGATE) as well as the
patient organization German Allergy and Asthma
Foundation (Deutscher Allergie- und Asthma Bund,
DAAB) have cooperated.
Consensus conferences were held in Wiesbaden in
September 2017, in Mainz in March 2018, in Kas-
sel in June 2018, in Mainz in March 2019, and in
Hannover in September 2019. The recommendations
elaborated during the conferences are based on a lit-
erature search evaluating clinical studies, case series,
individual case reports, experimental investigations,
as well as participants’ experiences and theoretical
considerations. Case series were assigned the highest
level of relevance, whereas theoretical considerations
were only included when neither single case reports
nor case series or experimental investigations were
available for evaluation. The number of scientifically
reliable studies on anaphylaxis is overall so limited
that management remains empirical in many aspects
and is often based on pathophysiological considera-
tions.
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